Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659726 | 1.00 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL13306399 | 1.00 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL2650619 | 0.93 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL13306402 | 0.91 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL4779278 | 0.91 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2654316 | 0.91 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL2654767 | 0.91 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2652955 | 0.91 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL2654104 | 0.91 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2659957 | 0.89 | GCK (0.77) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | claimed |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | GCK, GCKR, HK1 | GCK 1/4885KCNH2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.